Rivastigmine ((S)-N-ethyl-N-methyl-3-[1-(dimethylamino)ethyl]-phenyl carbamate hydrogen-(2R,3R)-tartrate, FDA approved in 2000) shows a prolonged noncompetitive inhibitory action both in vivo and in vitro against other carbamate anti-AD drugs and preferentially influences the AChE of the hippocampus and cortex [40]. This evidence concerns the gene ACHE and Alzheimer disease.